P.A.W. Capital Corp lessened its position in shares of Celgene Co. (NASDAQ:CELG) by 16.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,000 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the quarter. Celgene accounts for 1.5% of P.A.W. Capital Corp’s portfolio, making the stock its 21st largest position. P.A.W. Capital Corp’s holdings in Celgene were worth $1,458,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of the company. Thompson Davis & CO. Inc. raised its holdings in Celgene by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the period. Arcadia Investment Management Corp MI raised its holdings in Celgene by 118.7% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares during the period. Motco raised its holdings in Celgene by 19.3% in the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares during the period. Penserra Capital Management LLC acquired a new position in shares of Celgene during the second quarter valued at approximately $129,000. Finally, Balentine LLC raised its holdings in shares of Celgene by 83.5% during the second quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 481 shares during the last quarter. 79.74% of the stock is owned by institutional investors and hedge funds.
Celgene Co. (NASDAQ CELG) traded up $1.42 during trading on Friday, reaching $106.00. The company’s stock had a trading volume of 8,748,713 shares, compared to its average volume of 6,330,000. Celgene Co. has a one year low of $94.55 and a one year high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The firm has a market capitalization of $83,460.00, a PE ratio of 25.00, a PEG ratio of 0.67 and a beta of 1.77.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same period last year, the firm earned $1.58 earnings per share. Celgene’s quarterly revenue was up 10.2% on a year-over-year basis. analysts anticipate that Celgene Co. will post 6.69 earnings per share for the current year.
A number of equities analysts have commented on CELG shares. BMO Capital Markets increased their target price on Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a report on Friday, November 17th. Oppenheimer reissued a “buy” rating and set a $170.00 target price on shares of Celgene in a report on Friday, October 20th. Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 target price for the company in a report on Monday, October 23rd. Cann reissued a “buy” rating on shares of Celgene in a report on Thursday, October 26th. Finally, Morgan Stanley upgraded Celgene from an “underweight” rating to an “equal weight” rating in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $131.18.
ILLEGAL ACTIVITY NOTICE: “P.A.W. Capital Corp Trims Stake in Celgene Co. (CELG)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/p-a-w-capital-corp-has-1-46-million-holdings-in-celgene-co-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.